Author + information
- Toshiyuki Kimura,
- Nehiro Kuriyama,
- Akihiko Matsuyama,
- Keiichi Ashikaga,
- Shuichiro Sagara,
- Makoto Furugen,
- Tatsuya Nakama,
- Toshinobu Ishikawa,
- Yoheiu Inoue,
- Yusuke Fukushima,
- Kenji Ogata and
- Yoshisato Shibata
In–stent restenosis (ISR) has been significantly decreased by the use of drug–eluting stent (DES). But as the increasing use of DES, the treatment of DES restenosis lesions has become another global problem. Outcomes of second–generation DES implantation to the first–generation DES restenosis lesions were unknown. We evaluate the efficacy of Everolimus–eluting stent (EES) implantation to the Sirolimus–eluting stent (SES) restenosis lesions.
After the introduction of EES, we started a single–center registry to evaluate the efficacy of EES implantation to the SES restenosis lesions. 81 lesions were entered the registry and those were compared with 67 lesions of repeated SES implantation to the SES restenosis lesions. All patients were clinically and angiographically followed at 8–month after re–intervention.
Except for the patient age (70.8±7.3 years in EES group and 67.2 ± 8.6 years in SES group : p = 0.01), there were no significant differences of baseline patient and lesion characteristics between two groups. At 8–month follow–up, EES implantation to the SES restenosis lesions reduced binary restenosis rate (11.1% vs. 29.9%; p < 0.01) and target lesion revascularization (8.6% vs. 22.4%; p = 0.02) compared with repeated SES implantation. Repeated SES implantation was an independent predictor of re–restenosis compared with EES implantation.
To treat the SES restenosis lesions, EES implantation has the power of prevention from the re–restenosis.
8–Month Clinical Outcomes
|Target Lesion||EES in SES (n=81)||SES in SES (n=67)||p value|
|Reference diameter (mm)||2.79±0.38||2.88±0.47||0.21|
|Diameter stenosis (%)||22.9±27.6||30.8±34.1||0.12|
|Re-restenosis||9 (11.1%)||20 (29.9%)||<0.01|
|TLR||7 (8.6%)||15 (22.4%)||0.02|
|Late lumen loss (mm)||0.55±0.74||0.73±1.07||0.21|
|Stent thrombosis||1 (1.2%)||2 (3.0%)||0.45|
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.–10:45 a.m.
Session Title: Coronary Stents
Abstract Category: 47. TCT@ACC–i2: Coronary Intervention, Devices
Presentation Number: 2101–250
- 2013 American College of Cardiology Foundation